Nevertheless, it was confirmed that PD-1 overexpression was not vital for apoptosis; PD-L1 expression on tumor cells, as evaluated by immunohistochemistry (IHC), has emerged as the most widely studied biomarker for leading PD-L1/PD-1 inhibitor therapy. Here, PDCD1 is linked to neoplasm.